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In Memoriam: E. Donnall Thomas
Paul J. Martin, John A. Hansen
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WashingtonOn behalf of our colleagues and the readers of this journal,
we note the recent passing of E. Donnall Thomas, MD, whose
pioneering vision and perseverance fathered the ﬁeld of
hematopoietic cell transplantation across a time span of
40 years, from its conception and early embryonic stages in
the 1950s, prenatal gestation in the 1960s, infancy and early
childhood in the 1970s, adolescence in the 1980s, and
maturation into early adulthood during the 1990s. Mile-
stones included the identiﬁcation of marrow as a source of
transplantable hematopoietic stem cells in humans; the use
of total body irradiation to eliminate malignant cells in the
recipient and to prevent rejection; the application of histo-
compatibility typing to identify suitable related donors; the
use of immunosuppressivemedications tominimize the risks
of rejection and graft-versus-host disease; the implementa-
tion of measures to prevent and control deadly bacterial,
viral, and fungal infections; and expansion of the donor pool
through the use of HLA-matched unrelated volunteers.
Dr. Thomas was born on March 15, 1920, the son of
a physician in south Texas. As a child, he sometimes
accompanied his father on home visits to see patients. At the
University of Texas at Austin, he studied chemistry and
received his bachelor’s degree in 1941 andmaster’s degree in
1943. In 1946, he received his MD degree from Harvard
University.
In 1955, Dr. Thomas was recruited to the Mary Imogene
Bassett Hospital in Cooperstown, New York, where he began
his preclinical studies of marrow transplantation in a canine
model. Clinical efforts to control advanced leukemia by1083-8791/$ e see front matter  2013 American Society for Blood and Marrow
http://dx.doi.org/10.1016/j.bbmt.2012.11.019marrow transplantation from identical twin donors had
some initial success, but the early studies with allogeneic
donors did not. Insights into the genetics of allogeneic donor
selection emerged fromwork with the canine model after he
moved to the University of Washington in 1963.
By 1969, the Seattle team led by Dr. Thomas was prepared
to resume clinical efforts with allogeneic donors. Against
all odds, small numbers of desperately ill patients with
far-advanced leukemia survived after marrow trans-
plantation from HLA-identical sibling donors. Success rates
improved considerably during the 1970s, when the use of
bone marrow transplantation was extended to patients with
less-advanced disease. The 1980s were marked by improved
control of graft-versus-host disease and the advent of unre-
lated donor transplantation.
The discoveries and contributions of Dr. Thomas were
recognized by the Nobel Prize in Physiology or Medicine,
which he shared with Dr. Joseph E. Murray in 1990. In his
Nobel Lecture titled “Bone Marrow TransplantationdPast,
Present and Future,” Dr. Thomas recounted not only his own
work, but also the many historical contributions of other
investigators. He anticipated further improvement in
methods for eliminating malignant cells and controlling
infection and graft-versus-host disease. He predicted that
gene therapy would emerge for correction of congenital
hematopoietic diseases and highlighted the importance of
insights gained from preclinical animal models.
Throughout his career, Dr. Thomas emphasized that the
secret of his success came from the many talented individ-
uals who joined him in his work. First and foremost among
these was Dottie, his wife, with whom he shared his life and
professional accomplishments throughout their 70 years
together. In a magnetic way, he attracted a highly diverse
team of people with skills in medical subspecialties, nursing,
laboratory medicine, transfusion medicine, nutrition, phar-
macology, and laboratory research, all inspired by the cures
that bone marrow transplantation could provide. He nour-
ished the ﬁeld and disseminated his work by welcoming
visitors from other institutions.
Together with Dottie, members of the Thomas family,
and the many colleagues and friends privileged to be
included in the extended Thomas family, we mourn Don’s
death. Our sorrow is balanced by gratitude for his vision and
perseverance, his remarkable ability to prevail in the face of
adversity, and his profound inﬂuence in fathering the ﬁeld.
We honor his memory through our continued dedication to
furthering the success of his legacy in hematopoietic cell
transplantation.Transplantation.
